PostDoc Fellow - Mechanisms of acquired resistance to BTK inhibition in DLBCL: strategies to prolong the duration of

This job is no longer active. View similar jobs.

POST DATE 2/20/2017
END DATE 5/6/2017

AstraZeneca Pharmaceuticals LP Waltham, MA

Waltham, MA
AJE Ref #
Job Classification
Full Time
Job Type
Company Ref #
Entry Level (0 - 2 years)
Bachelors Degree


div class="overview-left" div class="job-location job-info" b Location: /b Waltham, Massachusetts, United States br /div b Job reference: /b R-003864 br br b Posted date: /b Mar. 10, 2017 br br ul style="margin-top:40px;" /ul /div br br div class="ats-description" itemprop="description" p At AstraZeneca we believe in the potential of our people and you’ll develop beyond what you thought possible. We make the most of your skills and passion by actively supporting you to see what you can achieve. We need great people who share our passion for science and have the drive and determination to meet the unmet needs of patients around the world. If you’re curious about what science can do, then you’re our kind of person. /p p Cancer is one of the greatest challenges facing medical science today. In our Oncology Team, you’ll push the boundaries of science every day to overcome that challenge. We’ve been at the center of some of the biggest breakthroughs in oncology. In lung cancer, for example, we’ve brought together complementary expertise to aid discovery and accelerate development in new medicines through a variety of partnerships and initiatives. We’re also early adopters of new technologies to support innovation, including CRISPR, genome editing techniques and a next-generation sequencing platform for companion diagnostics in oncology. But we’re not stopping there. With a world-class pipeline and some of the best experts in the industry, we’re in a great position to develop even more innovative therapeutic approaches. br /p p b Main duties and responsibilities /b br /p p Several potent and selective irreversible BTK inhibitors, including acalabrutinib have been developed for clinical use in B cell malignancies. Encouraging responses have been observed in diffuse large B Cell lymphoma (DLBCL), but responses are variable and, in patients that do respond, only a subset maintain durability beyond 12 months. /p p In this postdoctoral role, you’ll focus on identifying signatures in DLBCL that link to BTK inhibition sensitivity, and on understanding how adaptive resistance contributes to relapse in DLBCL patients on BTK inhibition therapy. /p p Our highly motivated and experienced multidisciplinary oncology drug discovery team are focused on bringing new medicines to cancer patients. By joining this team your primary objectives will be to: /p ul li Establish in vitro and in vivo sensitivity to the BTK inhibitor acalabrutinib across a panel of DLBCL models that represent the molecular and genetic diversity of DLBCL disease segments /li li Characterize BCR pathway inhibition and key components of homeostatic signaling, following short term and chronic acalabrutinib treatment across the DLBCL panel /li li Identify pathways contributing to adaptive resistance following acalabrutinib treatment /li li Define and test strategies to overcome adaptive resistance to acalabrutinib br /li /ul